NCT00516802View on ClinicalTrials.gov

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Melanoma Neoplasms
Interventions
DRUG

KU-0059436 (AZD2281)(PARP inhibitor)

oral

DRUG

dacarbazine

intravenous injection over at least 20 minutes

Trial Locations (4)

Unknown

Research Site, Pittsburgh

Research Site, London

Research Site, Manchester

Research Site, Oxford

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

KuDOS Pharmaceuticals Limited

INDUSTRY

lead

AstraZeneca

INDUSTRY